Abstract: | EDITED BY Joanna Zawitkowska, Medical University of Lublin, Poland REVIEWED BY Desiree Caselli, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Italy Agnieszka Mizia-Malarz, Medical University of Silesia, Poland *CORRESPONDENCE Chun Chen chenchun@mail.sysu.edu.cn Hongman Xue xuehongman@sysush.com Yucai Cheng chengyucai@sysush.com † These authors have contributed equally to this work SPECIALTY SECTION This article was submitted to Pediatric Hematology and Hematological Malignancies, a section of the journal Frontiers in Pediatrics RECEIVED 07 February 2023 ACCEPTED 23 March 2023 PUBLISHED 25 April 2023 CITATION Li Y, Liu Y, Wen L, Chen H, Wang W, Tian M, Cheng Y, Xue H and Chen C (2023) Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant. Front. Pediatr. 11:1160929. doi: 10.3389/fped.2023.1160929 COPYRIGHT © 2023 Li, Liu, Wen, Chen, Wang, Tian, Cheng, Xue and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. TYPE Original Research PUBLISHED 25 April 2023 DOI 10.3389/fped.2023.1160929 Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant Yixian Li1†, Yong Liu1†, Luping Wen2, Hui Chen3, Wenqing Wang1, Mengyao Tian1, Yucai Cheng1*, Hongman Xue1* and Chun Chen1* 1 Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China, 2Department of Pharmacy, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China, 3Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China Objective: To summarize the clinical characteristics of children with hematological malignancies co-infected with novel coronavirus and explore the safety and effectiveness of Paxlovid treatment. Methods: From December 10, 2022, to January 20, 2023, the clinical data of children with hematological diseases diagnosed with novel coronavirus infection in the outpatient and emergency department of the Seventh Affiliated Hospital of Sun Yat-sen University were retrospectively analyzed. Results: According to whether to give paxlovid or not, it is divided into group A (paxlovid group) and group B (non-paxlovid group). The length of fever was 1–6 days in group A and 0–3 days in group B. The viral clearance time was shorter in group A than in group B. The inflammatory indexes CRP and PCT were significantly higher in group A than in group B (P < 0.05). Twenty patients were followed up for 1 month after leaving the hospital, and there were 5 cases of reappearance of fever, 1 case of increased sleep, 1 case of physical fatigue and 1 case of loss of appetite within 2 weeks. Conclusions: Paxlovid has no apparent adverse reactions in children 12 years old and younger with underlying hematological diseases infected with the new coronavirus. Focusing on the interaction between paxlovid and other drugs is necessary during the treatment. KEYWORDS clinical efficacy, PAXLOVID,..